JUN and neoplasm: In particular, a recently proposed innovative strategy relies on CAR T cells over-expressing C-Jun, a transcription factor belonging to the AP-1 family, that resulted in resistance to exhaustion, enhanced in vivo expansion, reduced terminal differentiation and higher anti-tumor potency (52).